Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the successful closing of its public offering. The offering comprised 6,665,000 shares of common stock…
BostonGene, a leader in AI-driven molecular and immune profiling solutions, and Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have announced a master agreement…
Samsara Vision, a company dedicated to restoring vision and independence to patients suffering from late-stage age-related macular degeneration (AMD) through advanced visual prosthetic devices, has successfully completed its first SING…
GRO Biosciences Inc. (“GRObio”), a pioneering biotechnology firm utilizing synthetic biology to enhance the amino acid repertoire and advance protein therapeutics, has successfully concluded an oversubscribed Series B financing round,…
Bristol Myers Squibb (NYSE: BMY) has announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), unveiled new four-year findings from the RHONE-X extension study today. The study successfully met all primary endpoints, underscoring…
Research findings published today in the peer-reviewed Journal of Clinical Oncology by NMDP℠ and CIBMTR® (Center for International Blood and Marrow Transplant Research®) indicate that there is no significant difference…
Diakonos Oncology Corporation (“Diakonos”), a pioneer in immuno-oncology, announced today that its dendritic cell vaccine (DCV) for pancreatic ductal adenocarcinoma has received Fast Track designation from the U.S. Food and…
Spotlight Medical, a pioneering startup developing AI-driven prognosis tests to assist physicians in selecting the most effective treatment for cancer patients, has secured €6.2 million in seed funding. The investment…
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the first patient has been dosed in a Phase 1/2 trial…
Pint Pharma is pleased to announce that ORLADEYO® (berotralstat) has been approved by the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru for daily oral use in the…
Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or “Company”), a clinical-stage biotechnology firm pioneering targeted virotherapies, has confirmed that its Board of Directors has sanctioned a reverse stock split of…